Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Winston

Showing results (231-240 of 241) with videos related to

Pageof 25
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2021
CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort StudiesFabienne Caby, Marguerite Guiguet, Laurence Weiss, et al.
BMJ Open|November 22, 2011
A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsAngela M Minassian, Rosalind Rowland, Natalie E R Beveridge, et al.
HIV Medicine|July 27, 2012
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012Ian Williams, Duncan Churchill, Jane Anderson, et al.
HIV Medicine|December 17, 2013
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.), Ian Williams, Duncan Churchill, et al.
Eclinicalmedicine|January 23, 2023
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2Alex J Szubert, Katrina M Pollock, Hannah M Cheeseman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 10, 2017
Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological ConditionsEllen C Caniglia, Andrew Phillips, Kholoud Porter, et al.
Eclinicalmedicine|January 19, 2022
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trialKatrina M Pollock, Hannah M Cheeseman, Alexander J Szubert, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 5, 2022
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency VirusSarah Fidler, Julie Fox, Timothy Tipoe, et al.
The Lancet. HIV|June 21, 2021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trialJohn Frater, Katie J Ewer, Ane Ogbe, et al.
JCI Insight|February 22, 2022
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIVAne Ogbe, Matthew Pace, Mustapha Bittaye, et al.
Pageof 25

Showing results (231-240 of 241) with videos related to

Sort By:
Pageof 25
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2021
CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort StudiesFabienne Caby, Marguerite Guiguet, Laurence Weiss, et al.
BMJ Open|November 22, 2011
A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsAngela M Minassian, Rosalind Rowland, Natalie E R Beveridge, et al.
HIV Medicine|July 27, 2012
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012Ian Williams, Duncan Churchill, Jane Anderson, et al.
HIV Medicine|December 17, 2013
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.), Ian Williams, Duncan Churchill, et al.
Eclinicalmedicine|January 23, 2023
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2Alex J Szubert, Katrina M Pollock, Hannah M Cheeseman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 10, 2017
Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological ConditionsEllen C Caniglia, Andrew Phillips, Kholoud Porter, et al.
Eclinicalmedicine|January 19, 2022
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trialKatrina M Pollock, Hannah M Cheeseman, Alexander J Szubert, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 5, 2022
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency VirusSarah Fidler, Julie Fox, Timothy Tipoe, et al.
The Lancet. HIV|June 21, 2021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trialJohn Frater, Katie J Ewer, Ane Ogbe, et al.
JCI Insight|February 22, 2022
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIVAne Ogbe, Matthew Pace, Mustapha Bittaye, et al.
Pageof 25